Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?
Phase 4 Clinical Trial to Examine the Role of Rosuvastatin and Exercise Treatment in Modulating Inflammatory Response in Hypercholesterolemic Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Indiana
-
West Lafayette, Indiana, United States, 47906
- Purdue University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Nonfamilial hypercholesterolemia
- Total cholesterol >200 mg/dl, LDL >130 mg/dL
- Physical inactivity
- Moderate to low alcohol intake
Exclusion Criteria:
- Liver or kidney disease
- Acute illness or infection
- Use of corticosteroids, ACE inhibitors, platelet aggregating inhibitors, thiazolidinediones, and bis-phosphonates.
- Use of cyclosporine, warfarin, gemfibrozil or other lipid lowering agents
- Regular antacid or aspirin use
- Type I & II diabetes with insulin treatment
- hypothyroidism, and/or renal insufficiency
- Chronic/debilitating osteoarthritis
- Rheumatoid arthritis
- Central or peripheral nervous system disorders
- Anti-depressant medications
- Major affective disorder
- HIV infection or auto-immune disorders
- Use of tobacco products
- unexplained or intended weight loss of > 2 kg during the previous six months
- Surgery within the previous three months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The following measures will be made at 0, 10 and 20 weeks:
|
|
Monocyte cell-surface expression of TLR4, CD14, and CD16
|
|
LPS-stimulated whole blood production of IL-6 and TNF-α
|
|
Serum levels of hsCRP and TNF-α
|
|
Serum levels of Endotoxin LDL, OxLDL, HDL, sCD14, and
|
|
Lipopolysaccharide Binding Protein.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Creatine kinase & ALT (0, 5, 10 weeks; rosuvastatin group)
|
|
Creatine kinase & ALT (48hrs after 1st and 5th exercise
|
|
bout; rosuvastatin + exercise group)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Robert E Hannemann, MD, Purdue University
- Study Director: Michael G Flynn, PhD, Purdue University
Publications and helpful links
General Publications
- Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, McFarlin BK, Timmerman KL, Coen PM, Felker J, Talbert E. Influence of exercise training and age on CD14+ cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun. 2005 Sep;19(5):389-97. doi: 10.1016/j.bbi.2005.04.003.
- McFarlin BK, Flynn MG, Campbell WW, Stewart LK, Timmerman KL. TLR4 is lower in resistance-trained older women and related to inflammatory cytokines. Med Sci Sports Exerc. 2004 Nov;36(11):1876-83. doi: 10.1249/01.mss.0000145465.71269.10. Erratum In: Med Sci Sports Exerc. 2005 Feb;37(2):345.
- Methe H, Kim JO, Kofler S, Nabauer M, Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1439-45. doi: 10.1161/01.ATV.0000168410.44722.86. Epub 2005 Apr 28.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
Other Study ID Numbers
Other Study ID Numbers
- 0HQ01
- IRB Protocol Ref.#: 0504001888
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.